Beam Therapeutics Inc. reported an insider ownership change involving Amy Simon in a Form 4 filed on July 2, 2026, covering activity dated June 30, 2026. The filing reports a transaction in Beam’s common stock tied to the vesting of restricted stock units, rather than a discretionary open-market sale. According to the filing note, shares of Beam common stock were automatically sold on June 30, 2026, in a non-discretionary transaction to satisfy tax withholding obligations arising from the vesting of certain restricted stock units. Those RSUs had originally been granted to the reporting person on June 30, 2022, under Beam Therapeutics’ 2019 Equity Incentive Plan. The transaction was carried out under a Rule 10b5-1 trading plan adopted by Amy Simon on May 19, 2023. Such plans are typically established in advance to permit scheduled or formula-based transactions, helping distinguish routine administrative sales from discretionary trades based on current market information. The text provided does not include the number of shares sold, the sale price, a transaction code, or Amy Simon’s post-transaction ownership total. The key reported action is therefore the automatic sale of Beam common stock to cover taxes triggered by RSU vesting, an event commonly associated with equity compensation rather than a direct reduction of exposure for investment reasons.